Kyntra Bio
KYNB
152 hedge funds and large institutions have $950M invested in Kyntra Bio in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 50 reducing their positions, and 17 closing their positions.
555% more call options, than puts
Call options by funds: $28.2M | Put options by funds: $4.3M
27% more capital invested
Capital invested by funds: $747M → $950M (+$203M)
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
1% more funds holding
Funds holding: 150 → 152 (+2)
2% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 50
0.09% more ownership
Funds ownership: 3.03% → 3.12% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$9.79M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$9.52M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$6.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.1M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.53M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.92M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$5.88M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.94M |
KYNB Hedge Fund Activity: Q3 2022 in Review
152 of the 5,827 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2022, worth a combined $950M — up 27% from $747M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KYNB positions and 17 closed out — a net gain of 3 holders — while 51 added to existing stakes and 50 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $35.4M. The largest seller was Federated Hermes, cutting an estimated $11.1M.
- 152 institutional investors held Kyntra Bio (KYNB) as of Q3 2022, up from 150 in Q2 2022.
- Funds reported $950M of Kyntra Bio stock for Q3 2022, up 27% quarter-over-quarter.
- 20 funds opened new Kyntra Bio positions in Q3 2022 and 17 closed out, a net change of +3 holders.
- The largest Kyntra Bio buyer in Q3 2022 was Adage Capital Partners, an estimated $35.4M added.
- The largest Kyntra Bio seller in Q3 2022 was Federated Hermes, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2022.